187 related articles for article (PubMed ID: 31053175)
1. Evaluation of the impact of single-nucleotide polymorphisms on treatment response, survival and toxicity with cytarabine and anthracyclines in patients with acute myeloid leukaemia: a systematic review protocol.
Puty TC; Sarraf JS; Do Carmo Almeida TC; Filho VCB; de Carvalho LEW; Fonseca FLA; Adami F
Syst Rev; 2019 May; 8(1):109. PubMed ID: 31053175
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Li X; Xu S; Tan Y; Chen J
Cochrane Database Syst Rev; 2015 Jun; (6):CD010432. PubMed ID: 26037486
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
Cao HX; Miao CF; Yan L; Tang P; Zhang LR; Sun L
J Transl Med; 2017 Nov; 15(1):235. PubMed ID: 29141648
[TBL] [Abstract][Full Text] [Related]
5. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
6. Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia.
He H; Yin J; Li X; Zhang Y; Xu X; Zhai M; Chen J; Qian C; Zhou H; Liu Z
Eur J Clin Pharmacol; 2015 Mar; 71(3):293-302. PubMed ID: 25567217
[TBL] [Abstract][Full Text] [Related]
7. Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).
Zhu KW; Chen P; Zhang DY; Yan H; Liu H; Cen LN; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Chen XP
J Transl Med; 2018 Apr; 16(1):90. PubMed ID: 29631596
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.
Gamazon ER; Lamba JK; Pounds S; Stark AL; Wheeler HE; Cao X; Im HK; Mitra AK; Rubnitz JE; Ribeiro RC; Raimondi S; Campana D; Crews KR; Wong SS; Welsh M; Hulur I; Gorsic L; Hartford CM; Zhang W; Cox NJ; Dolan ME
Blood; 2013 May; 121(21):4366-76. PubMed ID: 23538338
[TBL] [Abstract][Full Text] [Related]
9. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review.
Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Montesinos P
Ann Hematol; 2018 Jul; 97(7):1115-1153. PubMed ID: 29680875
[TBL] [Abstract][Full Text] [Related]
10. Genomic Variants of Cytarabine Sensitivity Associated with Treatment-Related Mortality in Pediatric AML: A Report from the Children's Oncology Group.
Phillips CL; Lane A; Gerbing RB; Alonzo TA; Wilkey A; Radloff G; Lange B; Gamazon ER; Dolan ME; Davies SM
Clin Cancer Res; 2020 Jun; 26(12):2891-2897. PubMed ID: 32122921
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia.
Megias-Vericat JE; Martinez-Cuadron D; Herrero MJ; Alino SF; Poveda JL; Sanz MA; Montesinos P
Curr Drug Metab; 2018; 19(1):55-74. PubMed ID: 29090664
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
Wang H; Xiao X; Xiao Q; Lu Y; Wu Y
Medicine (Baltimore); 2020 Jun; 99(24):e20094. PubMed ID: 32541448
[TBL] [Abstract][Full Text] [Related]
13. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
van Dalen EC; Raphaël MF; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2014 Sep; (9):CD006647. PubMed ID: 25188452
[TBL] [Abstract][Full Text] [Related]
14. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
15. Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia.
Wang B; Zhang J; Hua X; Li H; Wang Z; Yang B
Sci Rep; 2020 Jan; 10(1):685. PubMed ID: 31959790
[TBL] [Abstract][Full Text] [Related]
16. Real-World Outcomes of Patients with Acute Myeloid Leukemia in Taiwan: A Nationwide Population-Based Study, 2011-2015.
Wang CY; Huang HH; Chen HM; Hsiao FY; Ko BS
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e649-e657. PubMed ID: 33931380
[TBL] [Abstract][Full Text] [Related]
17. A prediction model for complete remission upon reinduction for patients with acute myeloid leukemia after failure of anthracycline and cytarabine standard chemotherapy.
Kim DY; Lee JH; Sym SJ; Yun SC; Lee JH; Kim SD; Choi Y; Lee YS; Kang YA; Jeon M; Seol M; Lee KH; Lee YJ; Lee KH
Ann Hematol; 2011 Nov; 90(11):1283-91. PubMed ID: 21484304
[TBL] [Abstract][Full Text] [Related]
18. Management of acute myeloid leukaemia--5 years experience at Armed Forces Bone Marrow Transplant Centre, Rawalpindi.
Ullah K; Ahmed P; Raza S; Satti TM; Chaudhry QU; Akhtar F; Kamal MK; Akhtar FM; Khan B
J Pak Med Assoc; 2007 Sep; 57(9):434-9. PubMed ID: 18072636
[TBL] [Abstract][Full Text] [Related]
19. Hypomethylating agents and chemotherapy in MDS.
Adès L; Santini V
Best Pract Res Clin Haematol; 2013 Dec; 26(4):411-9. PubMed ID: 24507817
[TBL] [Abstract][Full Text] [Related]
20. Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL)).
Küley-Bagheri Y; Kreuzer KA; Monsef I; Lübbert M; Skoetz N
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD011960. PubMed ID: 30080246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
